Boryung Pharm Asset Resilience Ratio
Boryung Pharm asset resilience ratio. Boryung Pharm (003850) has an Asset Resilience Ratio of 8.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 003850 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Boryung Pharm (2009–2024)
Asset resilience ratio of Boryung Pharm from 2009 to 2024. This chart shows how Boryung Pharm's Asset Resilience Ratio has changed over time. Read 003850 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Boryung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Boryung Pharm balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩116.42 Billion | 8.59% |
| Total Liquid Assets | ₩116.42 Billion | 8.59% |
Asset Resilience Insights
- Limited Liquidity: Boryung Pharm maintains only 8.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Boryung Pharm Industry Peers by Asset Resilience Ratio
Compare Boryung Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Boryung Pharm Asset Resilience Ratio by Year (2009–2024)
Boryung Pharm asset resilience ratio by year from 2009 to 2024. The table below shows the annual Asset Resilience Ratio data for Boryung Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.40% | ₩4.67 Billion ≈ $3.17 Million |
₩1.16 Trillion ≈ $788.89 Million |
+0.01pp |
| 2023-12-31 | 0.39% | ₩3.59 Billion ≈ $2.44 Million |
₩915.51 Billion ≈ $620.43 Million |
+0.19pp |
| 2022-12-31 | 0.21% | ₩1.84 Billion ≈ $1.25 Million |
₩892.39 Billion ≈ $604.76 Million |
-5.92pp |
| 2021-12-31 | 6.12% | ₩50.73 Billion ≈ $34.38 Million |
₩828.64 Billion ≈ $561.56 Million |
-3.94pp |
| 2020-12-31 | 10.06% | ₩65.21 Billion ≈ $44.19 Million |
₩647.99 Billion ≈ $439.14 Million |
+10.02pp |
| 2019-12-31 | 0.04% | ₩213.73 Million ≈ $144.85K |
₩507.63 Billion ≈ $344.01 Million |
-0.01pp |
| 2018-12-31 | 0.05% | ₩213.18 Million ≈ $144.47K |
₩450.02 Billion ≈ $304.97 Million |
-0.01pp |
| 2017-12-31 | 0.05% | ₩214.70 Million ≈ $145.50K |
₩402.52 Billion ≈ $272.78 Million |
-0.05pp |
| 2016-12-31 | 0.10% | ₩410.37 Million ≈ $278.10K |
₩397.90 Billion ≈ $269.65 Million |
+0.10pp |
| 2012-12-31 | 0.00% | ₩3.82 Million ≈ $2.59K |
₩273.01 Billion ≈ $185.01 Million |
0.00pp |
| 2011-12-31 | 0.00% | ₩3.76 Million ≈ $2.55K |
₩262.39 Billion ≈ $177.82 Million |
+0.00pp |
| 2010-12-31 | 0.00% | ₩2.29 Million ≈ $1.55K |
₩245.86 Billion ≈ $166.61 Million |
0.00pp |
| 2009-12-31 | 0.00% | ₩2.29 Million ≈ $1.55K |
₩176.79 Billion ≈ $119.80 Million |
-- |
About Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, So… Read more